APN431 / Apeiron Biologics - LARVOL DELTA

Expansion of APEIRON Biologics and Domainex Partnership will Advance Cancer Drug Discovery (Pharmtech) - "The expansion of the companies’ partnership will integrate lead optimization efforts to advance cancer immune therapy drug discovery...Under this agreement, Domainex will provide its expertise in medicinal and computational chemistry, screening, structural biology, and absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME/PK) to advance APEIRON’s Cbl-b targeting compound series, APN431, towards pre-clinical development."

Licensing / partnership • Oncology